Navigation Links
INDIGO Biosciences Announces Release of Assay Kit for Testing Multi-Drug Resistance
Date:6/19/2019

INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the addition of the Human MDR-1 / P-Glycoprotein Drug Interaction Assay to their portfolio. This kit expands INDIGO’s existing in vitro toxicology offerings and allows researchers to perform critical toxicology testing previously available only through contract services into their own labs.

“The addition of the MDR1 assay to INDIGO’s portfolio gives discovery scientists the ability to get results quickly on one of the most critical aspects of drug development. By combining our nuclear receptor expertise and additional predictive toxicology indicators such as MDR1, researchers can be confident that they are ready to take the next step in development,” says Dr. Jack Vanden Heuvel, Chief Scientific Officer of INDIGO. Dr. Vanden Heuvel was also awarded a Podium Presentation at the 2019 Society of Toxicology Annual Meeting to share data and research utilizing the new MDR1 assay, along with the Company’s new gene expression and predictive liver toxicity assays, with the drug discovery and development communities.

The Multidrug Resistance Protein 1 (MDR1) plays a critical role in the removal of foreign substances – such as toxins or drugs – from the body by protecting cells from toxification. MDR1 activators range from pollutants, such as those encountered through unintended exposure to industrial and agricultural chemicals, to drugs administered for therapeutic benefit.

A drug that is either a substrate or inhibitor of MDR1 can profoundly impact the rate of absorption, distribution, or excretion of co-administered drugs, leading to significant changes in their effectiveness and potential toxicity. The MDR1 multidrug resistance transporter impacts the development of antibiotics, chemotherapy drugs, and mortality. MDR1 interaction is often cited as a precursor to drug-drug interactions on product labels and particularly in the use of digoxin, a common heart medication used to treat heart failure and heart rhythm problems. Not surprisingly, assessing the potency of this interaction, and thus the potential for drug-drug interactions, is mandated by the FDA.

The new assay kit offered by INDIGO Biosciences contains all necessary materials to allow for two independent 48-well assay setups. Each aliquot of cells is provided as a single-use reagent, though both may be combined to run one full assay plate. MDR1 Drug Interaction Assay utilizes the Company’s proprietary CryoMite™ preservation process, allowing for exceptional cell viability post-thaw and eliminating the need for cumbersome intermediate steps. As with INDIGO’s other product offerings, the testing process takes only 24 hours, providing researchers with clear, reproducible data without the longer wait times associated with most alternative testing options.

About INDIGO Biosciences, Inc.
INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making. INDIGO supplements the world’s largest portfolio of nuclear receptor kits and services and in vitro toxicology solutions with greater results readability, reproducibility, and faster turnaround times. Our solutions, plus supportive team and reliable science and platforms aim to reduce the time, cost, and risk associated with the discovery process. Learn more at http://www.indigobiosciences.com

Read the full story at https://www.prweb.com/releases/indigo_biosciences_announces_release_of_assay_kit_for_testing_multi_drug_resistance/prweb16389063.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Kenall’s Indigo-Clean® and SenScape™ -- Winners of 2018 Product Innovation Awards
2. DuPont Nutrition & Biosciences Launches Biobased Enzymes for Medical Instrument Cleaning
3. Algal Omega-3 Innovators Ben Kelly of Algarithm Ingredients and Philip Bromley of Virun Nutra-Biosciences Speak at Algae Biomass Summit 2018
4. Locus Biosciences Secures $5m Convertible Note for CRISPR-Cas3 Antimicrobials
5. Therapix Biosciences to Ring the Nasdaq Stock Market Opening Bell on June 28
6. Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June
7. Therapix Biosciences Ltd. Announces Full Exercise of Underwriters Over-Allotment Option
8. 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
9. Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
10. Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS
11. Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2019)... ... , ... Intelligent.com, a trusted resource for online degree rankings ... for 2020. The comprehensive research guide is based on an assessment of 67 ... curriculum quality, graduation rate, reputation, and post-graduate employment. , The 2020 rankings ...
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex Health, ... invasive technologies to treat chronic pain in soft and hard tissue, recently achieved ... technology. , Dr. Bernard Morrey, Chief Medical Officer of Tenex Health, ...
(Date:12/2/2019)... , ... December 02, 2019 , ... ... of A Mission for Michael, an intensive mental health facility, announced it has ... oversee client relations, business development and national advocacy efforts. , "We are proud ...
Breaking Medicine Technology:
(Date:12/5/2019)... ... December 05, 2019 , ... It’s ... launching exceptional products that help people embrace, achieve, and maintain a healthy lifestyle ... been more committed to our mission of impacting world health, so it’s gratifying ...
(Date:12/4/2019)... ... 2019 , ... A November 12 article on NBC Connecticut reported ... options. The article highlighted the life-changing or life-ending consequences of some E-scooter accidents, from ... rider fatality after an incident with a vehicle. Los Angeles-based personal injury law firm ...
(Date:12/4/2019)... ... December 04, 2019 , ... WEDI , the nation’s leading nonprofit ... exchange and a trusted advisor to the U.S. Department of Health and Human Services ... announced during the 2019 WEDI Winter Conference in Arlington, Va. on Wednesday, December 4. ...
(Date:12/4/2019)... ... December 04, 2019 , ... While the holidays are a time for joy ... Texas A&M AgriLife Extension Service specialists. , “There are many behavioral ... your overall wellness,” said Joyce Cavanagh, AgriLife Extension specialist in family economics, College Station. ...
(Date:12/4/2019)... ... December 04, 2019 , ... ... of AZD4041 for treating tobacco use and dependence. The study will investigate safety ... system (CNS) penetrant antagonist of orexin-1 (hypocretin-1) receptors that is being developed in ...
Breaking Medicine News(10 mins):